Christoph B. Olivier: Can We Stay Ahead of Valve Thrombosis?
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared RPTH Journal‘s post on LinkedIn, adding:
”Early signals in TAVR: Can we stay ahead of valve thrombosis?
I am proud to share this latest work from our Antithrombotic Research Group, now featured in RPTH Journal.
The question is critical: Can we identify which patients will develop HALT before it even shows up on a CT scan?
This study highlights the complexity of finding definitive clinical predictors.
Excellent work by Dr. David Hesselbarth and the entire team.”
Quoting RPTH Journal‘s post:
”Can we predict valve leaflet thrombosis before it shows up on CT after TAVR?
Hypoattenuated leaflet thickening (HALT) happens in up to one-third of TAVR patients, yet we still don’t know how to identify who’s at risk early.
This new prospective cohort study asked a simple but powerful question:
Can early post-procedure blood biomarkers signal future HALT?
Researchers followed TAVR patients and performed advanced hemostasis testing (TEG, platelet function, inflammation markers) shortly after the procedure, then checked CT scans 6 months later.
What they found:
- Moderate-to-severe HALT occurred in 20% of patients
- Early signals of hypercoagulability and inflammation emerged:
- Shorter clot formation time (TEG R-time)
- Higher platelet counts
- Elevated protein S
- Higher CRP levels
But, here’s the critical nuance: After correction for multiple testing, none remained statistically significant.
Translation:
We’re seeing biological signals, not definitive predictors… yet.
This study is a perfect example of how science moves forward:
From exploratory signals to hypothesis to larger trials to clinical tools.
Big questions for the field:
- Will functional coagulation testing become part of TAVR risk stratification?
- Is HALT partly driven by inflammation plus hypercoagulability?
- Could early biomarker profiling guide post-TAVR antithrombotic therapy?”
Title: Associations of biomarkers with hypoattenuated leaflet thickening after transcatheter aortic valve replacement
Authors: David Hesselbarth, Michelle D’Orazio, Giovanni Ciccarone, Diona Gjermeni, Carina Jülch, Philipp Breitbart, Philipp Ruile, Manuel Hein, Marius Wessinger, Mariya Maslarska, Jonathan Rilinger, Christopher Schlett, Fabian Bamberg, Klaus Kaier, Daniel Duerschmied, Torben Pottgiesser, Constantin von zur Mühlen, Dirk Westermann, Christoph B. Olivier
Read the Full Article on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health